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Abstract
Background
Dengue results in a significant public health burden in endemic regions. The World Health
Organization (WHO) recommended the use of warning signs (WS) to stratify patients at risk
of severe dengue disease in 2009. However, WS is limited in stratifying adult dengue
patients at early infection (Day 1–3 post fever), who require close monitoring in hospitals to
prevent severe dengue. The aim of this study is to identify and validate prognostic models,
built with differentially expressed biomarkers, that enable the early identification of those
with early dengue infection that require close clinical monitoring.
Methods
RNAmicroarray and protein assays were performed to identify differentially expressed bio-
markers of severity among 92 adult dengue patients recruited at early infection from years
2005–2008. This comprised 47 cases who developed WS after first presentation and
required hospitalization (WS+Hosp), as well as 45 controls who did not develop WS after
first presentation and did not require hospitalization (Non-WS+Non-Hosp). Independent val-
idation was conducted with 80 adult dengue patients recruited from years 2009–2012. Prog-
nostic models were developed based on forward stepwise and backward elimination
estimation, using multiple logistic regressions. Prognostic power was estimated by the area
under the receiver operating characteristic curve (AUC).
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Results
TheWS+Hosp group had significantly higher viral load (P<0.001), lower platelet (P<0.001)
and lymphocytes counts (P = 0.004) at early infection compared to the Non-WS+Non-Hosp
group. From the RNA microarray and protein assays, the top single RNA and protein prog-
nostic models at early infection were CCL8 RNA (AUC:0.73) and IP-10 protein (AUC:0.74),
respectively. The model with CCL8, VPS13C RNA, uPAR protein, and with CCL8, VPS13C
RNA and platelets were the best biomarker models for stratifying adult dengue patients at
early infection, with sensitivity and specificity up to 83% and 84%, respectively. These
results were tested in the independent validation group, showing sensitivity and specificity
up to 96% and 54.6%, respectively.
Conclusions
At early infection, adult dengue patients who later presented WS and require hospitalization
have significantly different pathophysiology compared with patients who consistently pre-
sented noWS and / or require no hospitalization. The molecular prognostic models devel-
oped and validated here based on these pathophysiology differences, could offer earlier
and complementary indicators to the clinical WHO 2009WS guide, in order to triage adult
dengue patients at early infection.
Introduction
Dengue results in a significant public health burden in the endemic regions, particularly in the
World Health Organization (WHO) South-East Asia andWestern Pacific Regions, accounting
for nearly 75% of the current global dengue disease burden [1–3]. Over decades, there is an
increasing trend of young adults requiring hospitalization due to dengue [4–7]. Specific antivi-
ral therapy is not available, making case management entirely supportive and a vaccine, is cur-
rently not widely available. The standard-of-care is directed towards constant monitoring of
patients with the aim of providing appropriate and timely fluid support, to prevent the devel-
opment of hypovolemic shock [3,8]. Besides the importance of early dengue diagnosis, an early
prognostic tool that predicts dengue severity and guides clinical triage to reduce severe dengue
progression and over-hospitalization is also critical [5,9–11]. In 2009, the WHO introduced a
revised dengue classification advocating clinicians to look out for clinical presentation of spe-
cific WS during triage, as indicators of possible severe dengue progression and to recommend
strict monitoring[1].
However, there are a number of challenges encountered when applying the WS-guided den-
gue classification among adult dengue patients. Firstly, it was reported to be too sensitive and
not specific enough in identifying severe illness, resulting in a significant increase in hospitali-
zation, workload of medical personnel and economic burden for resource-limited endemic
regions [6,12,13]. Secondly, WS generally occurred only one day prior to the development of
severe illness/ requirement of intervention, at 4–7 days post fever onset (p.f.), and this narrow
window makes any form of intervention challenging, particularly when appropriate healthcare
facilities are not accessible or available near their place of residences [6,8]. An earlier identifica-
tion of dengue patients who are at high risk of severe disease could also benefit the introduction
of therapeutic interventions, when developed [14], offering a longer window for therapy
response. Lastly, although the presence of anyWS was strongly associated with severe outcome,
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no single WS can independently predict disease progression, and hence the requirement for
close monitoring in hospital in order to fully characterize the WS. Only patients with noWS
were highly predictive of non-severe dengue outcomes and could be safely managed as outpa-
tients [15,16]. As such, further refinement of the triage process at the early infection stage for
patients who are likely to develop WS later and require hospitalization, would be particularly
useful in the primary healthcare setting to reduce dengue burden [12,17].
As the expression of host RNA and proteins are dynamic and sensitive to stimulus from
changes in environment, diet, metabolism as well as pathogen infection, the systematic analysis
of molecular features has been widely adopted for biomarker model discovery. Once identified
and validated, biomarkers of clinical value could be incorporated into numerous types of pre-
dictive tools, but preferably into rapid, point-of-care tests. [18,19].
In this study, we aim (1) to identify early molecular features predicting WS and hospitaliza-
tion requirement, (2) to build biomarker models for close monitoring requirement in hospitals,
(3) to evaluate performance of biomarker models to stratify patients at Day 1–3 p.f. who are at
higher risk of developing WS later and require hospitalization and (4) to perform an indepen-
dent validation for the top optimal prognostic models.
Methods
Study sites and population studied
The participants in the discovery cohort were 18 years of age who presented within 72 hrs
from acute onset of fever of 38°C or above, with no clinically obvious alternative diagnosis
to fever at the participating primary care polyclinics in Singapore, as part of the early dengue
infection and control study (EDEN) conducted from years 2005–2008, described in previous
publications [20–22]. The participants in an independent validation cohort also had the
same inclusion and exclusion criteria but were recruited from years 2009–2012. Participants
who had a positive dengue polymerase chain reaction (PCR) test were included in this
study. Blood and serum samples from the participants were collected at three time points
(at Day 1–3 p.f., Day 4–7 p.f. and three to four weeks p.f.). These study cohorts are outlined
in Fig 1.
Dengue classification and warning signs criteria
The 2009 WHO dengue severity classification based on clinical signs and symptoms were
applied in this study. This divides patients into “probably dengue”, “dengue with warning signs
(WS)” and “severe dengue”. The WS stated in the guidelines are; abdominal pain or tenderness,
persistent vomiting, clinical fluid accumulation, mucosal bleed, lethargy, restlessness, persistent
vomiting, liver enlargement>2cm and increase in HCT concurrent with rapid decrease in
platelet account. Severe dengue was defined by severe plasma leakage, severe bleeding and/or
severe organ impairment [1]. In the EDEN study, only three WS were recorded during the
study period from year 2005–2008. They were abdominal pain, mucosal bleeding and persis-
tent vomiting. Persistent vomiting was defined as vomiting at two study clinic visits and/or one
study clinic visit and during hospitalization. Severe plasma leakage was defined as either a
pulse pressure difference of less than 20 mmHg, a systolic pressure of less than90 mmHg in
need of intervention, pleural effusion or ascites. Pleural effusion and ascites was diagnosed
with chest x-ray/ultrasound. Severe bleeding was defined as internal bleeding requiring trans-
fusion. Severe organ impairment was considered as liver AST or ALT>1000 and CNS:
impaired consciousness.
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Hospital admission criteria
The decision to hospitalize a patient was left to the discretion of the treating physician. How-
ever, national guidelines on dengue management are available and are adopted by the health-
care institutions in Singapore. Hospitalization criteria in these guidelines include: significant
bleeding, fall in blood pressure, dehydration and postural hypotension, rise in hematocrit of
20% or greater compared to the baseline, platelet count<80,000 cells/mm3, severe vomiting or
diarrhea, severe abdominal pain, and elderly patients with co-morbidities who are unwell.
Clinical data and sample management
A standardized case report form (CRF) was used for collecting clinical data. Additionally,
venous blood for hematological and molecular analyses was collected. Clinical data and sam-
ples were obtained at time of inclusion (within 72 hrs post fever onset), at time of defervescence
(4–7 days post fever onset) and finally at time of convalescence (3–4 weeks post fever onset).
The clinical data for hospitalized patients were obtained from the electronic medical records.
Hematology and serology
A full blood count was performed on anticoagulated whole blood collected at all three time
points. A bench-top, FDA-approved hematocytometer was used for this application (iPoch-
100, Sysmex, Japan). Calibration by internal and external QC controls was also performed on a
Fig 1. Selection workflow of dengue patients with warning signs that required hospitalizations and patients with no warning signs and no
hospitalization required for both discovery and validation cohort.
doi:10.1371/journal.pone.0155993.g001
Early Biomarkers of Adult Dengue Patients with Warning Signs
PLOS ONE | DOI:10.1371/journal.pone.0155993 June 10, 2016 4 / 19
regular basis. IgM and IgG antibodies against dengue virus were detected using commercially
available ELISAs (PanBio, Brisbane, Australia) according to manufacturer’s instructions.
Viral detection and quantification
RNA was extracted using QIAamp Viral RNA mini kit (Qiagen, Hilden, Germany) according
to the manufacturer’s protocol. Dengue virus RNA detection was carried out by PCR using a
set of generic pan-dengue primers that targeted the 3’ non-coding region of dengue viruses as
previously described [23]. Results were analyzed with the Light Cycler software version 3.5.
Reactions with high crossover threshold (Ct) value or ambiguous melting curve results were
further analyzed by electrophoresis on a 2% agarose gel, to confirm the presence of the cor-
rectly sized amplicon. Quantification of viremia was performed by a Taqman based PCR using
earlier published primers and probes detecting DENV 1–4 [24]. Standard ABI conditions were
used, incorporating primers at 900nM and probes at 50nM.
Microarray
Total RNA (500ng) was amplified in a single-round of IVT amplification that allowed incorpo-
ration of Biotin-labeled nucleotides using the Illumina1 TotalPrep™ RNA Amplification Kit
(Ambion, Inc., Austin, TX) according to the manufacturer’s instructions. cRNA (850ng) of
each sample was hybridized to an Illumina HumanRef-8 V3.0 BeadChip following the manu-
facturer’s instructions (Illumina, Inc., San Diego, CA). This was followed by washing, blocking,
and streptavadin-Cy3 staining steps and finally by scanning with a high resolution Illumina
Bead Array Reader confocal scanner, all carried out following manufacturer’s instructions
(Illumina, Inc., San Diego, CA).
Microarray normalization and gene selection
The detection p-value was calculated by Beadstudio software (Illumina). Standard normaliza-
tion procedures (GenespringGX software; version10.0; Silicon Genetics) for one colour array
data were used. In brief, array (mean) normalization accounted for chip variability was per-
formed by dividing all of the measurements on each chip by a 75th percentile value. After nor-
malization, the data was filtered according to flags present there at least 75% of the samples in
any 1 of the 2 conditions had flags present leaving 6844 genes for further analyzes. Significance
Analysis of Microarray (SAM) was used to detect transcripts that were relatively more or less
abundant in one group of samples. SAM also corrected significance values for multiple testing
using a false discovery rate threshold of 5%. False discovery rate of less than 5 percent and fold
difference of at least 1.5 fold were used to identify the significant genes. Pathway analysis was
done using Ingenuity Pathway Analysis software (version 7.5; Ingenuity Systems).
Measurement of RNA expression using Fluidigm technology
In order to develop a potential point-of-care device, a simple PCR based technology should be
applied instead of using a microarray based technology, to reduce cost and processing time.
Fluidigm platform was used. The required amount of RNA is 500ng/10ul per reaction. The
protocols were according to the manufacturer’s recommended instructions. Briefly, cDNA is
synthesized through reverse transcription using MultiScribe reverse transcriptase with the fol-
lowing program: 25°C for 10 min, 37°C for 120 min, 85°C for 5 min and 4°C for 30min. This is
followed by pooling of Taqman assays and pre-amplification reaction with the following pro-
gram: 95 for 10min, and 14°C cycles of 95°C for 15sec and 60°C for 4 min. Lastly, this is fol-
lowed on with final amplification using the BioMark and the 48.48 dynamic array as instructed
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in the manufacturer’s instructions. The signal of the gene expression was normalised by 18S
rRNA expression. The expression level and quality control checks were determined using the
BioMark Real-Time PCR Analysis Software.
Protein measurements
Serum samples collected were assayed for 22 cytokines and chemokines (S2 Table) related to
inflammation and immune using a luminex bead array approach (Bioplex) (BioRad Carlsbad,
CA) according to the manufacturer’s protocol. Quantitative sandwich enzyme-linked immuno-
sorbent assays (ELISA) were used to measure fibrinogen (Immunology Consultants Laboratory
Inc, Newberg, OR), urokinase plasminogen activator receptor (uPAR) as well as IP-10 (R&D
Systems, Minneapolis, MN). The assay from R&D Systems was needed as a significant number
of serum samples from dengue patients had concentration of IP-10 above the detection range
of the Bioplex system. All assays were carried out according to the manufacturers’ instructions.
Statistical analyses
For descriptive analysis, Pearson’s chi-square and Fisher’s exact tests were used to compare cat-
egorical variables. Mann-Whitney U test and Student T-test were used to compare continuous
variables with non-normal distribution (age and viral load) and normal distribution, respec-
tively. Univariate and multivariate logistic regression were used to calculate crude and adjusted
odds ratios (COR; AOR), respectively with 95% confidence intervals (CI) reported. P-value of
<0.05 was considered as statistically significant. All statistical analyses were performed using
Stata 10.0 (Stata Corp., College Station, TX, 2005).
Biomarkers selection and prognostic model development
RNA and proteins biomarkers that were significantly different (P<0.05) between the two
groups at Day 1–3 p.f. were selected and ranked accordingly from the most significance
(P<0.01) to the least significance (P = 0.05) for the model development. Model development
was based on forward stepwise and backward elimination estimation using multiple logistic
regressions. Prognostic performance was based on the area under the receiver operating char-
acteristic curve (AUC), Hosmer-Lemeshow Goodness-Of-Fit (GOF) test, and likelihood ratio.
Models were also compared with the inclusion of three laboratory variables (viral load, plate-
lets, and lymphocytes), as well as the three warning signs (abdominal pain, mucosal bleeding
and persistent vomiting) that are recorded in the EDEN study from 2008–2009.
Ethical approval
The study protocol was approved by the National Healthcare Group Domain Specific Review
Board (DSRB B/05/013), as well as the Institutional Review Boards of the National University of
Singapore and DSO National Laboratories. Enrolment of study participants was conditional on
appropriate written informed consent administered by designated qualified study research nurse.
Results
Between May 2005 and December 2008, a total of 1,315 suspected dengue patients were
enrolled. Among the 212 (16%) patients who had RT-PCR confirmed dengue infection, 54
were excluded due to missing data/samples. Of the remaining 158 patients, 76 patients had at
least one of the three WS and 82 patients had no WS (Fig 1). There were 47 patients who later
developed WS and were subsequently hospitalized (WS+Hosp. Group; Fig 1). These patients
were representative of those that should be prioritized for strict monitoring and interventions
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at early infection according to the 2009 WHO dengue severity classification [1]. Furthermore,
45 patients who did not develop WS and were not hospitalized (Non-WS+Non-Hosp. Group;
Fig 1) represented a group of mild dengue patients that were safely managed as outpatients.
Twenty-nine patients with warning signs were not hospitalized and 37 patients without warn-
ing signs were hospitalized (Fig 1).
All these patients were followed longitudinally at our study clinics for the scheduled three
visits. Of the 47 patients in the WS+Hosp. Group, 14 (30%) progressed to severe disease as
defined by the 2009 WHO dengue severity classification [1].None of the patients in the Non-
WS+Non-Hosp. Group and the not hospitalized patients with WS developed severe dengue
disease (Fig 1). Five out of 37 (14%) patients in the group of hospitalized patients without WS
developed severe dengue. No deaths were reported in any of the groups. Participants who later
developed WS but were not hospitalized were excluded from our discovery cohort as it was not
possible to undertake detailed severity assessments without serial daily measurements. More-
over, participants who did not develop WS but were hospitalized, were excluded as they were
likely admitted due to non-dengue concerns (such as deterioration of other co-morbid condi-
tions) or on non-clinical grounds (such as lack of adequate care at home).
Clinical and laboratory characteristics of discovery cohort
Among theWS+Hosp. group, 44 (94%), 10 (21%) and 5 (11%) reported mucosal bleeding, persis-
tent vomiting and abdominal pain, respectively. Only six (14%) patients had signs of mucosal
bleeding at Day 1–3 post fever onset (p.f.), while 14 (32%) had signs at Day 4–7 p.f., and 27 (61%)
had signs at time of hospitalization. Moreover, 32 (73%) showed signs of bleeding during hospital-
ization. Gum bleeding was the most common (n = 18) followed by skin (n = 12), menstrual bleed-
ing (n = 8), nose bleeding (n = 5), hematuria (n = 3) and per rectal bleeding (n = 2). Six patients
reported persistent vomiting at both Day 1–3 p.f. and Day 4–7 p.f., while nine reported it at Day
4–7 p.f. and during hospitalization. Two patients had abdominal pain at Day 1–3 p.f. while three
patients had abdominal pain at Day 4–7 p.f. The patients in theWS+Hosp. group were admitted
at a median of 4 days (range 1–7) p.f. and hospitalized for a median of 3 days (range 1–7)
(Table 1). Among patients with severe dengue, 6 had severe plasma leakage, 5 had severe bleeding
(2 hematuria, 3 rectal bleeding) and 3 had severe organ involvement (transaminase>1000 U/L).
During hospitalization, 44 out of 47 (94%) patients received intravenous fluid replacement.
There were significant differences (P<0.05) in viral, platelet and lymphocyte levels between
the WS+Hosp. and Non-WS+Non-Hosp. groups at Day 1–3 p.f. (Fig 2). Within the WS+Hosp.
group, there was no significant differences in viral, platelet and lymphocyte levels at Day 1–3 p.
f. between the 14 patients who progressed to severe dengue and the remaining 33 patients with
no progression to severe dengue (S1 Fig). However, severe dengue patients showed the same
significantly higher viral, lower platelet and lymphocyte levels compared to the Non-WS+Non-
Hosp; as the WS+Hosp. group did (S2 Fig). This illustrates the similar pathophysiological char-
acteristics at Day 1–3 between patients with WS that develop severe dengue and those patients
with WS who do not. However, there are clear differences in pathophysiological characteristics
between the Non-WS+Non-Hosp. group compared to both the WS+Hosp. group and the WS
+Hosp. patients who progress to severe dengue, suggesting that pathophysiological characteris-
tics can be used to distinguish these groups (independently of WS).
Differential biomarkers betweenWS+Hosp. group and Non-WS+Non-
Hosp. group at early infection
A total of 23 RNA biomarkers were differentially expressed at Day 1–3 p.f. with1.5 fold dif-
ference (P<0.05; S1 Table) between the WS+Hosp. group and the Non-WS+Non-Hosp.
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group. Eight of these 23 genes are related to innate immune activation, namely CCL2, CCL3,
CCL8, CD69, NFIL3, RIN2, CYP27A1 and CDKN1C. Among the immune-related biomarkers,
only IL-8, CCL2, CCL3 and CCL8 were differentially expressed between Non-WS+Non-Hosp.
group and severe dengue group (P<0.05; S1 Table).
Out of the 22 protein biomarkers analyzed, the WS+Hosp. group had significantly higher
level of four proteins at Day 1–3 p.f. than the Non-WS+Non-Hosp. group, namely interferon
gamma-induced protein (IP)-10 (P = 0.0001), interleukin (IL)-1ra (P = 0.0094), fibrinogen
(FGA) (P = 0.0423) and urokinase-type plasminogen activator receptor (uPAR) (P = 0.0047)
(S2 Table). The WS+Hosp. group had significantly lower level (P = 0.0207) of RANTES than
the Non-WS+Non-Hosp. group at Day 1–3. However, only CCL4, IP-10 and uPAR were dif-
ferentially expressed between Non-WS+Non-Hosp. group and severe dengue group (P<0.05;
S3 Table).
Table 1. Demographic descriptions of dengue RT-PCR positive patients classified according to designated clinical outcomes.
EDEN 2005–2008 (Discovery Cohort) EDEN 2009–2012 (Validation Cohort)
Non-WS + Non-
Hosp.
WS + Hosp. Non-WS + Non-
Hosp.
WS + Hosp.
(N = 45) % (N = 47) % p-value (N = 55) % (N = 25) % p-value
Age
Median (Range) 41 (21–63) 37 (19–77) 0.229# 33 (25.5–42.5) 41 (25–52) 0.211#
Gender
Female 22 48.9 23 48.9 0.996 7 12.7 10 40 0.006
Ethnicity
Chinese 32 71.1 39 83.0 31 56.4 16 64.0
Malay 1 2.2 4 8.5 5 9.1 6 24.0
Indian 7 15.6 3 6.4 8 14.5 1 4.0
Others 5 11.1 1 2.1 0.082 11 20.0 2 8.0 0.122
Pre-Existing Comorbid
Yes 7 15.6 6 12.8 0.701 3 5.5 4 16 0.196^
Serotype
1 16 35.6 25 53.2 3 5.5 3 12
2 13 28.9 14 29.8 35 63.6 19 76
3 16 35.6 8 17.0 0 0 2 8
4 0 0 0 0 0.098 6 10.9 1 4 0.011
Unknown 0 0 0 0 11 20 0 0
IgG Status at Presentation
Positive 20 44.4 25 53.2 0.401 20 36.4 17 68 0.009
Hospitalization
Median days p.f. on admission (Range) n.a. 4 (1–7) n.a. 5 (1–8)
Length of stay (Range) n.a. 3 (1–7) n.a. 4 (2–9)
Severe Disease
Yes 0 0 14 30.0 <0.001^ 0 0 1 4 0.312^
# Mann-Whitney Test
^ Fisher’s Exact Test
p.f.—post fever onset
n.a.–not applicable
Statistically signiﬁcant p-values are in bold
doi:10.1371/journal.pone.0155993.t001
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Prognostic performance of RNA and protein biomarker models at early infection. The
IP-10 protein (Model 1; AUC = 0.74) and CCL8 RNA (Model 3; AUC = 0.73) biomarkers were
the top single biomarker models for protein and RNA, respectively (Table 2). Among the mul-
tiple biomarker models developed (and shown in Table 2), Model 13 (CCL8, VPS13C RNA,
and uPAR protein) and Model 14 (CCL8, VPS13C RNA, and Platelets Level) had the greatest
AUC of about 0.90 and 0.88, respectively, and both were more parsimonious than Model 12
(HIST14HE, VPS13C RNAs, and IL-1RA, uPAR proteins). With the probability cutoff at 0.5,
Fig 2. Laboratory characteristics (A-Viral copy number at Day 1–3; B-Platelet count; C-Lymphocytes
count) of hospitalized dengue patients with warning signs (WS + Hosp. Group) compared to non-
hospitalized patients with no warning signs (Non-WS + Non-Hosp. Group). P-value (P) is shown only for
statistically significant comparisons on Day 1–3 and Day 4–7 between the two groups.
doi:10.1371/journal.pone.0155993.g002
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Model 13 had a sensitivity of 82.9%, specificity of 80.0%, positive predictive value (PPV) of
80.6% and a negative predictive value (NPV) of 82.4%; while Model 14 had sensitivity of 80.9%
sensitivity, 84.4% specificity, PPV of 80.6% and a NPV of 82.4%. The sensitivity and specificity
may be optimized by varying the probability cut-off, as shown in Fig 3.
Models which comprised of a single laboratory parameter (platelets, viral, lymphocytes) or
warning sign (abdominal pain, persistent vomiting and mucosal bleeding) were not as effective
as Model 13 and 14 (Table 2).Even though the multiple biomarker marker Model 21(platelets,
Table 2. Early prognostic models of warning signs and hospitalization from the discovery cohort.
Model Variables (RNA/Proteins/Lab/Warning Signs) AUC Sen (%) Spe (%) PPV (%) NPV (%) GOF test (p-value)
Models without Laboratory Features
1 IP-10 0.7353 54.35 77.78 71.43 62.50 0.57
2 IL-1ra 0.7348 55.32 84.44 78.79 64.41 0.29
3 CCL8 0.7277 72.34 66.67 69.39 69.77 0.14
4 HIST1H4E 0.7229 76.60 55.56 64.29 69.44 0.06
5 PKD2L1 0.7047 72.34 53.33 61.82 64.86 0.68
6 CCL3 0.6979 63.83 64.44 65.22 63.04 0.57
7 uPAR 0.6955 60.00 74.29 70.00 65.00 0.77
8 VPS13C 0.6950 61.70 53.33 58.00 57.14 0.05
9 RGL1 0.6946 68.09 53.33 60.38 61.54 0.70
10 NCOA7 0.6927 70.21 60.00 64.71 65.85 0.13
11 IP-10, CCL8 0.7942 71.74 73.33 73.33 71.74 0.48
12 HIST14HE, VPS13C, IL-1RAuPAR* 0.9045 82.86 77.14 78.38 81.82 0.62
13 CCL8, VPS13C, uPAR^§ 0.8988 82.86 80.00 80.56 82.35 0.24
Models with Laboratory Features
14 CCL8, VPS13C, Platelets Level^* 0.8757 80.85 84.44 84.44 80.85 0.32
15 Platelets Level 0.7390 72.34 68.89 70.83 70.45 0.84
16 Viral Ct Level 0.7058 73.91 56.82 64.15 67.57 0.56
17 Lymphocytes Level 0.6792 76.60 48.89 61.02 66.67 0.01#
18 Platelets and Viral Ct Level 0.8370 73.91 79.55 79.07 74.47 0.20
19 Platelets, Viral Ct Level, IP10 0.8520 77.78 81.82 81.40 78.26 0.08
20 Platelets Level, IP10 0.8097 76.09 77.78 76.09 77.78 0.33
21 Platelets, Viral Ct Level, CCL8 0.8696 84.78 79.55 81.25 83.33 0.02#
Models with Warning Signs
22 Abdominal Pain 0.5102 100.0 0 51.09 - N.A
23 Persistent Vomiting 0.5615 23.40 88.89 68.75 52.63 N.A
24 Mucosal Bleeding 0.5000 0 100 - 52.33 N.A
Internal Validation using Fluidigm for CCL8, VPS13C
13 CCL8, VPS13C, uPAR 0.8420 77.27 61.90 68.00 72.22 0.34
14 CCL8, VPS13C, PLT 0.8682 69.57 83.87 76.19 78.79 0.74
11 IP10, CCL8 0.7451 41.18 88.89 70 70.59 0.83
Sen- Sensitivity; Spe- Speciﬁcity; PPV- Positive predictive value; NPV- Negative predictive value; N.A.- Not applicable. Sen, Spe, PPV and NPV are
based on probability cutoff of 0.5.
^ Forward Stepwise Estimation from top 10 single RNA and protein molecules based on AUC
* Backward Elimination Estimation from top 10 single RNA and protein molecules based on AUC
§ Likelihood-Ratio test shows model 13 and 14 provide the same ﬁt as model 12 (p-value>0.05)
#Model has signiﬁcant lack of ﬁt for the data
GOF- Goodness-of-ﬁt test showed signiﬁcant “lack-of-ﬁt” when p<0.05.
doi:10.1371/journal.pone.0155993.t002
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Fig 3. Sensitivity and specificity plots of Model 13 (A) and Model 14 (B) with the varying probability
cut-offs using the discovery cohort. The y-axis shows the true positive rate (sensitivity in blue) and the true
negative rate (specificity in red) of the model’s capability at different probability cutoff on the x-axis. The
probability cutoff range (x-axis) allows the investigators to choose how sensitive and specific they want the
model to be at different setting depending on the aim of the models.
doi:10.1371/journal.pone.0155993.g003
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viral Ct level, and CCL8 RNA) had AUC of0.87, it does not fit the dataset well (Goodness-of-fit
test P<0.05). In order to evaluate the microarray results forCCL8, VPS13CRNAs, real-time
polymerase chain reaction technology (Fluidigm) was selected to validate the CCL8, VPS13C
RNA levels. Using Fluidigm as an internal validation with the same biological samples, Model
13 and 14 had similar AUC of 0.84 and 0.87, respectively (Table 2). This clearly illustrates the
potential of using PCR as a suitable platform for these RNA biomarkers.
Independent validation of the top two prognostic models
Between January 2009 and December 2012, there were 1,895 suspected dengue patients enrolled.
Among which, 117 (6%) patients were dengue RT-PCR positive. Using the same inclusion and
exclusion criteria as the discovery cohort (described in Fig 1), 25 dengue patients who presented
at Days 1–3 p.f. and hadWS with hospitalization were classified as the WS+Hosp. group, and 55
dengue patients who presented at Days 1–3 p.f. but did not haveWS and had no hospitalization
requirement were classified as the Non-WS+Non-Hosp. group. Patient characteristics are out-
lined in Table 1. Using this independent cohort for validation, model 13 achieved 64% sensitivity,
76% specificity, PPV of 55% and NPV of 82% at Days 1–3 p.f. (Table 3), while model 14 achieved
60% sensitivity, 78% specificity, a PPV of 56% and a NPV of 81% at Days 1–3 p.f. (Table 3). In
addition, various probability cutoffs were also assessed. With a probability cutoff of 0.2, the vali-
dation resulted in much higher sensitivity of 96% and a modest 55% specificity (Table 3).There
was only one patient with severe dengue in this validation cohort. Both models13 & 14 were able
to correctly classify this severe dengue patient into theWS+Hosp. group at Days 1–3 p.f. (Well
before the patient actually developedWS). We next assessed if the model predictions identified
patients that showed the characteristic pathophysiology differences observed in our discovery
process. Viral Ct value, platelets and lymphocyte levels were significantly different (P<0.01)
between the predictedWS + Hosp. group and the predicted Non-WS+Non-Hosp group in this
validation cohort at Day 1–3 p.f. except for platelets level between the two groups predicted by
Model 13 (Fig 4). Platelet level between the two groups predicted by Model 13 and 14 were signif-
icantly different at Day 4–7 p.f. (Fig 4B and 4E).
Discussion
The diverse clinical spectrum of dengue disease presentations is still a challenge for health care
workers in dengue endemic regions, especially to identify patients early that will later require
Table 3. Early prognostic performance of the top selectedmodels with an independent validation cohort across a range of probability cutoff.
Model Variables Probability Cutoff Sensitivity Speciﬁcity PPV NPV
1 IP-10 0.2 100.0 0 31.3 -
0.5 80.0 50.9 42.6 84.9
0.8 32.0 96.4 80.0 75.7
3 CCL8 0.2 96.0 16.4 34.3 90.0
0.5 48.0 67.3 40.0 74.0
0.8 8.0 98.2 66.7 70.1
13 CCL8, VPS13C, uPAR 0.2 96.0 49.1 46.2 96.4
0.5 64.0 76.4 55.2 82.4
0.8 40.0 90.9 66.7 76.9
14 CCL8, VPS13C, Platelets 0.2 96.0 54.6 49.0 96.8
0.5 60.0 78.2 55.6 81.1
0.8 32.0 94.6 72.7 75.4
doi:10.1371/journal.pone.0155993.t003
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clinical interventions to prevent progression to severe illness and particularly in adults. While
warning signs of the WHO 2009 dengue classification were found to be associated with severe
illness, they typically occurred only one day prior to the development of severe illness
[6,8,15,16], which would be a challenging window for any effective intervention. In this study,
we aimed to identify and validate biomarker models, comprised of distinct molecular features
at early dengue infection (Days 1–3 p.f.), that were associated with adult dengue patients who
would develop WS and require hospitalization, typically 3 to 5 days later.
Fig 4. Laboratory characteristics of patients in the validation cohort who are predicted at Day 1–3 p.f. to develop warning
signs and require hospitalization at post Day 1–3 p.f. using Model 13 (A, B and C) and Model 14 (D, E and F). Viral Ct level at
Day 1–3 (A, D), platelet (B, E) and lymphocyte (C, F) levels of the patients who were predicted into either the “Non-WS + Non-Hosp”
group or “WS + Hosp” group. WS- Warning Signs; Hosp-Hospitalisation. P-value (P) is shown only for statistically significant
comparisons on Day 1–3 and Day 4–7 between the two predicted groups.
doi:10.1371/journal.pone.0155993.g004
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The WHO 2009 WS guidelines and clinical judgment were applied to identify patients who
did and who did not require clinical observation, dividing the patients into two groups. Those
who later developed WS of abdominal pain, bleeding and/or persistent vomiting and were hos-
pitalized (WS+Hosp. group) and those who did not develop WS and did not require hospitali-
zation (Non-WS+Non-Hosp. group). We found that the WS+Hosp. group had significantly
higher viremia, but lower platelet and lymphocyte levels compared with Non-WS+Non-Hosp.
group at early infection (Days 1–3 p.f.). The Non-WS+Non-Hosp group has to our knowledge
not been previously reported in the literature and these novel observations clearly illustrated
viral (AUC = 0.71), platelet (AUC = 0.74) and lymphocyte (AUC = 0.68) levels as potential bio-
markers to triage patients into the two groups at early infection. Hospitalization typically
occurred at Day 4–7, and the platelet and lymphocyte levels were observed to be lower in the
WS+Hosp. group than Non-WS+Non-Hosp. group. This suggests that hospitalization due to
low platelet and lymphocyte levels was common in our cohort. The lack of statistical differ-
ences in viral, platelet or lymphocyte levels between the severe dengue group and the remaining
patients from the WS+Hosp. group (S1 Fig) highlights the difficulties in recognizing these
severe dengue patients at early infection, as they are likely to be indistinguishable from other
hospitalized patients with WS, even on Day 4–7 p.f. This reflects the similar observations
between children with severe illness and hospitalized non-severe illness published previously
[25]. However, the severe dengue patients were significantly different in pathophysiology from
the Non-WS+Non-Hosp. group at early infection (S2 Fig). High viremia has previously been
associated with severe dengue outcomes [21,22,26]. In our findings, we showed that early vire-
mia was significantly associated with the later development of WS and the requirement for
close hospital monitoring, as was platelet and lymphocyte levels; suggesting an important role
of these parameters in the development of dengue disease severity.
In this study, we focused our discovery work on a fully described group of patients with WS
and excluded those that were not hospitalized, in order to avoid patients who may have been
misclassified. However, it is possible that these excluded patients followed a milder disease.
These patients were all followed longitudinally at our study clinics for the scheduled three vis-
its. None of the 29 patients with WS who did not require hospitalization had severe disease as
assessed at their third visit compared to 30% of those in the WS+Hosp. group (Fig 1). In addi-
tion, the median platelet levels of these 29 patients at the first and second study clinic visit were
higher (189 and 139, respectively) as compared to the WS+Hosp. group (132 and 62 respec-
tively) and the hospitalized group of patients without WS (median platelet levels 136 and 77
respectively). This suggests that hospitalization was typically due to low platelet levels by the
time of second visit, rather than due to WS in our cohort. To compensate for this potential
bias, hospitalized patients without WS were also excluded from our discovery analysis.
The biomarkers associated with the WS+Hosp. group were involved in innate immunity
(CCL2, CCL3, CCL8, CD69, RANTES, IL1RA, IP-10) and coagulation (uPAR, FGA) pathways
that were previously associated with dengue severity [27–32] andmay be informative of the
strength of the innate response during early infection, which may be related to the progression
of disease severity after Day 1–3. CCL8 (MCP-2), the top RNA biomarker, is a chemokine that
had been previously associated as a biomarker for tuberculosis diagnosis [33] and outcome of
hepatitis C virus infection [34]. IP-10 (CXCL-10), the top protein biomarker is a pro-inflam-
matory chemokine [35], which has been highly associated as a biomarker to predict severity of
several inflammatory diseases including infectious diseases, immune dysfunction and tumor
development [36]. In our best prognostic analysis, Models 13 & 14, we also utilized uPAR pro-
tein and VPS13C RNA. Soluble uPAR is a versatile signaling proteinase receptor [37] that had
been suggested as a biomarker to predict survival of HIV-1 infection [38] and to discriminate
primary focal segmental glomerulosclerosis [39], which may also be related to the protective
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PLCE1 loci associated with DSS [40]. Furthermore, VPS13C RNA encodes for a vascular pro-
tein associated with the pathophysiology of type-2 diabetes [41], which may further support
the association of diabetes with dengue severity [42]. While these biomarkers showed high bio-
logical relevance to dengue pathophysiology, they may not fully explain the development of
severe disease, as this may also be influenced by other, as yet undefined, mechanisms.
Many of the WS stated by the WHO 2009 classification are typically seen on Day 4–7 p.f. in
the clinical course of disease [6,15,16]. Mucosal bleeding was a commonWS in our cohort and
in others [6,15], and a majority of the patients showed this WS, mainly during admission into
hospital at Day 4–7 p.f. and during hospitalization, which was also observed in other studies
[6,43]. Similar to other studies [6,15], our study also showed that some WS, namely abdominal
pain (AUC = 0.51), persistent vomiting (AUC = 0.56) and mucosal bleeding (AUC = 0.50),
had less optimal prognostic performance in this cohort, reemphasizing the importance to
assess the molecular biomarker as a potential prognostic tool.
Ideally, in primary healthcare facilities, the clinician should have a reliable test that can diag-
nose and predict at Day 1–3 p.f., if a patient had dengue and may progress to severe disease
which requires prompt close monitoring and hospitalization. Our findings showed that by
combining RNA and protein biomarkers, the best model (CCL8, VPS13C RNAs, and uPAR
protein) gave 82.9% sensitivity, 80.0% specificity in the discovery cohort. Furthermore, by add-
ing platelet counts to the biomarkers, a model (CCL8, VPS13C RNAs, and Platelets) that gave
81% sensitivity and 84% specificity was established. When validated in an independent cohort,
the top two models achieved modest sensitivity and specificity of about 64% and76%, respec-
tively for Model 13 (CCL8, VPS13C RNAs and uPAR), and 60% and 78%, respectively for
Model 14 (CCL8, VPS13C RNAs and Platelets). However, with the importance of sensitivity in
triage, the models may achieve sensitivity and specificity up to 96% and 54.6%, respectively,
with a different probability cutoff. Moreover, these models may be tested simultaneously with
the dengue virus PCR assay as diagnosis, to additionally guide prompt clinical triage. Further-
more, we showed that by using our models 13 and 14, we were able to accurately predict the
expected significant differences in pathophysiology between the WS+Hosp group and the
Non-WS+Non-Hosp. group. In addition, both models 13 & 14 are able to identify patients
who are likely to present with thrombocytopenia (predicted WS+Hosp. group) or not (pre-
dicted Non-WS+Non-Hosp. group) at Day 4–7 p.f. when they first presented to the clinicians
at Day 1–3 p.f. with no thrombocytopenia.
The generalizability of these optimal models may be limited until further validation is per-
formed in a larger cohort of adult dengue patients. While the observed different predominant
serotype in the discovery and validation cohorts demonstrates some generalizability in the vali-
dation group, across both serotypes 1 and 2 viruses, nevertheless, further more diverse studies
are required. It may be that single biomarker prediction models such as IP-10 protein and
CCL8 RNAmay be more robust when tested in larger number of patients, even though they
may not be the most optimal in this study (Table 2). The small proportion of severe dengue
patients in our study reflects both the early stage of recruitment and the distinct nature of adult
disease [6]. Therefore, it was statistically challenging to develop optimal models in stratifying
patients of high risk of severe dengue. Nevertheless, our data highlights the need to focus
resources on the small group of patients who are likely to develop WS later with hospitalization
requirement, to prevent severe disease progression. Lastly, innovation will be needed to reduce
the cost and complexity of the current methods used to detect multiple RNA transcripts and
protein simultaneously with a blood test based application, particularly for application in a
developing countries.
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Conclusion
In summary, this is the first study, to our knowledge, that has shown adult dengue patients
who later developed WS with hospitalization requirement have different pathophysiological
features at Day 1–3 p.f. compared to adult dengue patients who did not develop WS and had
no hospitalization requirement. Potential prognostic biomarkers models were developed from
highly associated laboratory and molecular features, for triage at early infection, of adult den-
gue patients who are likely to develop WS later with hospitalization requirement. With future
independent larger cohort for validation, these optimal models may be applied to complement
the WHO 2009 dengue classifications. These biomarkers models would be best integrated with
viral detection assays as a potential point-of care tool for both dengue diagnosis and disease
prognosis, to guide clinical triage and treatment simultaneously and could be particularly use-
ful if antivirals become available to treat dengue infection.
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